ACROSS Global™

WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 4,100 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that "every drug can be made and every disease can be treated."

Pentagrit is a zebrafish discovery lab offering efficacy screening services. Facilities includes state of art zebrafish facility for pre-clinical development across segments Oncology, Inflammation, Gene Therapy, Metabolic and Cardiovascular, Neurology and Infectious diseases.

Zebrafish Gene Therapy Programme
Immunogenicity Optimizer for Vector and Target DNA

Zebrafish Tumor Programme
Diffuse Intrinsic Pontine Glioma
Pancreatic Tumor
(NSCLC) Lung Cancer
Leukemia

Zebrafish Metabolic Programme
Left Ventricular Hypertrophy
Type II Diabetes
Obestity
NASH and NAFLD

Zebrafish Neuronal Programme
Parkinson’s
Alzheimer’s
Multiple Sclerosis

Zebrafish Rare Disease Programme
RETT Syndrome
Batten Disease

Zebrafish Pain Programme
Intestinal Pain
Peripheral Pain

Zebrafish Inflammation Programme
Arthritis
Psoriasis

Zebrafish Infection Programme
Dengue
Malaria
Chikungunya
Sars CoV-2

CMIC Group pioneered the CRO business in Japan over 28 years ago. Since then CMIC has continued as a leading innovator in the industry and has expanded services to encompass the entire pharmaceutical value-chain. We pride ourselves on meeting customers where they are and with exactly what they need to move their products forward.

TRIUMPHARMA was founded in 2002 , is a full service CRO that supports the pharmaceutical and the biotech industries in introducing new solutions to the pharmaceutical markets, with core strength in :
Clinical Trials [Phase I - Phase IV] including Clinical Data Management and BE/BA studies.

Over the years we have successfully conducted more than 300+ US-FDA submissions , EU/ANSAM/Bfarm/MHRA submissions (NDAs & ANDAs) and MENA/JFDA submissions, using HVs and patients in various therapeutic areas such as CV diseases, Gastro-intestinal disorders, Respiratory/Pulmonary disorders, Metabolic disorders, Endocrinology, Nephrology/Hepatology, Rheumatoid Arthritis Disorders of immune systems, Neurology/Psychiatry, Gynecology, Acute/Chronic infections and Oncology.

TRIUMPHARMA has experience in many of the POC indications, in addition to our experience in early phase studies such as Asthma, NASH, Parkinson, AF, Diabetes, and others. We have also conducted many studies on monoclonal antibodies including HAE and biosimilar /biotech products.

TRIUMPHARMA encompass a total bed capacity of 80 beds across our two floors ((over 200 beds with our hospital sites) and 5 LC/MS/MS machines. We have a dedicated facility and team for Phase I-IV clinical trials conducted in compliance with ICH GCP guidelines. And we have our own diagnostic and screening medical lab, Bioanalytical lab with state of the arts LC/MS/MS equipment’s, the trained PIs, Research Nurses, CRCs, CRAs, Project Management, certified and trained Spirometer technicians, dedicated Data Entry team with familiarity with the relevant and most updated clinical software’s used in trials, Qualified site and IMPs Depot .We are also able to offer our clients the benefit of a large collective experience when formulating and implementing regulatory strategies and study designs.

We have successfully been inspected by US-FDA , EMA, French Ministry of Health-ANSM, German Ministry of Health- Bfarm, Turkish MOH, GCC, UAE MOH, JFDA,

Ajanta Pharma Limited (APL) is a pharmaceutical company headquartered in Mumbai, India. It has strong presence in Branded Generic business in India & Emerging markets; and Generic business in USA.

In India, company operates in selected therapeutic areas of Cardiology, Dermatology, Ophthalmology and Pain management. It's brands hold leadership positions in sub-therapeutic areas they are present in.

In Emerging Markets, company has presences in Africa, South East Asia, West Asia, and CIS on broader therapeutic segments such as anti-malarial, gastro, antibiotics, cardiology, dermatology, pain management, etc.

As on 31 March 2021, Ajanta has 36 ANDA approvals which are commercialised. And it is awaiting US FDA approval for 15 ANDAs. Company plans to file 10-12 ANDAs during the current financial year.

Company has state-of-the-art research facilities for formulation and API development located at Mumbai, India. R&D capabilities are evident from number of 1st to market products launched by the company providing patients most needed compliance and convenience. A dedicated and focused team of over 650+ scientists work for R&D, which is growing continuously.

Ajanta has 6 formulations manufacturing facilities located in India and 1 in Mauritius. Besides that, it also has an API manufacturing facility located at Waluj, India. Ajanta’s flagship formulation facilities at Paithan (Maharashtra, India) and Dahej (Gujarat, India) have been approved by US FDA.

Ajanta continuously invests in enhancing the existing manufacturing facilities to meet current cGMP requirements and also construct new facilities to meet company’s growth requirements.

Please visit http://ajantapharma.com/ for more information.